The MHRA is kicking off a consultation to figure out if CE-marked medical devices should keep their recognition in Great Britain beyond the current temporary setup. This discussion revolves around possibly giving certain CE-marked devices indefinite recognition, along with some transitional and reliance measures.
The consultation started on February 16, 2026, and you’ve got until 11:59 PM on April 10, 2026, to weigh in. They’re looking for feedback from everyone involved in the medical tech scene before that deadline.
This move follows some transitional measures from 2023 that let CE-marked devices stay in the Great Britain market until 2030. Now they want to know if it makes sense to offer more long-term certainty, especially for devices that meet the EU Medical Device Regulation and the EU In Vitro Diagnostic Regulation as part of their broader regulatory reform efforts.
So, what’s on the table?
The MHRA wants to hear if CE-marked medical devices should still be recognized in Great Britain without a set expiration date. Right now, these devices have a transitional recognition running until 2030 to help smooth things over after Brexit and the introduction of the UKCA mark.
They’re exploring whether giving indefinite recognition for certain CE-marked devices could ensure steady market access past 2030. The goal here is pretty clear: support patient access to safe tech while also fostering innovation and growth in the UK health tech scene.
Just a heads up though, this is just a consultation at this point; no permanent changes are confirmed yet. What happens will rely heavily on what stakeholders submit before April 10, 2026.
Now, about that indefinite recognition.
CE marking shows that a device meets European regulatory standards like the EU Medical Device Regulation and EU In Vitro Diagnostic Regulation. Since Brexit, Great Britain has been doing its own thing with regulations and brought in the UKCA mark. But to keep things running smoothly, they allowed CE-marked devices to stay on the market until 2030 under transitional rules.
If they go ahead with indefinite recognition, it would mean that devices meeting EU MDR and EU IVDR could keep being sold in Great Britain without worrying about hitting an expiration date linked to 2030. This could cut down on duplicate assessments since those products already align with updated European requirements.
For manufacturers and others in the supply chain, this could bring more predictability when it comes to planning regulations and managing product lifecycles. Healthcare providers would also benefit from more stability in supply. But remember, since this is still up for discussion, we don’t yet have all the details about how any future recognition might work.
As for what feedback the MHRA is looking for, there are three main proposals they want input on:
First up is extending transitional arrangements for older devices certified under the previous EU Medical Devices Directive. They’re thinking about aligning timelines with updated EU deadlines so manufacturers can transition smoothly from MDD certification to comply with EU MDR while keeping safety standards intact.
Second, they’re looking at whether devices compliant with EU MDR and EU IVDR should get indefinite recognition in Great Britain instead of being stuck with that time-limited one that ends in 2030.
Thirdly, they’re proposing an international reliance route for devices classified more strictly in Great Britain than in the European Union. This means they’d consider approvals from trusted international regulators if classifications differ significantly. It’s all about easing extra regulatory burdens when possible.
These ideas show a potential shift towards a model that aligns better internationally while keeping domestic oversight intact.
Now who should really pay attention here? This consultation affects a wide array of folks. UK medical device manufacturers (especially small and medium-sized businesses) need to think about how indefinite recognition might shape their regulatory strategies or long-term market plans. Depending on how this plays out, they might reconsider their focus on UKCA conformity assessments.
Distributors and importers ought to look into how changes could affect labeling, registration processes, documentation, and inventory management too; changes might throw a wrench into supply agreements or operational workflows.
UK Responsible Persons play a crucial role ensuring compliance for non-UK manufacturers; any adjustments here could change their responsibilities concerning technical documentation or communication with regulators.
Approved Bodies and consultants may want to gauge how these proposals might affect demand for specific UK conformity assessments or advisory services as well.
NHS procurement teams and clinical stakeholders should also stay tuned since continuity in regulations can lead to more predictable access to devices (which helps avoid unexpected supply hiccups).
Trade associations and patient advocacy groups have a chance here too, to provide insights on innovation trends and patient access issues. The MHRA wants input from various stakeholders as they shape future policies.
From a practical standpoint for businesses: while this consultation isn’t changing anything right away, it’s a great time for strategic planning.
Companies might want to take stock of their regulatory strategies regarding UKCA versus CE certifications based on potential outcomes from this consultation. Mapping out which products rely on MDD certificates versus those compliant with EU regulations can help clarify things moving forward.
Cost analysis will also be key: businesses should weigh maintaining dual certification paths against potentially having indefinite CE recognition instead. The MHRA is looking for solid evidence here too, especially data related to burdens or supply impacts.
It’s essential also to think about resilience within the supply chain, considering whether these proposed changes will help or hinder consistent supply levels for healthcare providers across Great Britain is crucial too.
Remember though, these are just considerations; final requirements will depend on what comes out of government evaluations after consulting submissions wrap up.
If you want to respond to this consultation, you can do so through GOV.UK’s official page before April 10th at midnight.
Typically, stakeholders fill out an online questionnaire but can add written evidence as well. It’s wise for organizations to coordinate responses across different teams to make sure they’re sending a unified message backed by solid evidence before time runs out!
After everything’s submitted?
The MHRA will sift through responses and then publish what they conclude along with next steps, which could lead into wider changes as part of ongoing medical device reforms aimed at balancing patient safety with innovation while keeping international alignment in mind.
All said and done, this MHRA consultation marks an important moment for those involved in medical devices within Great Britain. With temporary recognition lasting till 2030 currently established via GOV.UK guidelines, the big question now is whether they’ll offer longer-term certainty specifically for those CE marked devices that meet EU regulations like MDR and IVDR.
Manufacturers, distributors – really anyone connected – the outcome matters! So be sure you review everything closely and get your thoughts into them by April 10th!